If you already have a Mounjaro (tirzepatide) pen in your hands and want to know it is genuine, the honest answer is that no single test settles it. You verify it by working through a short sequence: confirm the pen came through a licensed, documented pharmacy supply chain, match every printed detail on the carton, pen and invoice against the manufacturer's own data, and check the storage and serialisation features before you rely on it. This guide is written for detection and reporting only, after the April 2026 Gurugram seizures made counterfeit pens a documented concern in India.

• A genuine Indian Mounjaro pen is imported from the United States, not manufactured in India. A "made in India" label on the carton is a red flag.
• The supply chain is the strongest single control. A licensed pharmacy invoice is far harder to fake than packaging.
• India's track-and-trace system does not currently cover Mounjaro, so an absent government QR code does not prove a pen is fake.
• The three viral tests circulating on patient forums, the missing barcode, the government code scan, and the capital-S typography trick, are each unreliable as standalone checks.
• Authenticity is a pattern across source, paperwork, cold chain and serialisation, not any one feature.

Gather everything the pen arrived with. Verification depends on cross-referencing physical items against each other, so a missing invoice or a discarded carton removes a check you cannot get back.

• The pen itself, unopened if possible.
• The outer carton, including any leaflet.
• The pharmacy invoice, showing the pharmacy's name, address and licence details.
• Your prescription from a registered medical practitioner.
• A smartphone with a camera or a QR/barcode scanner app.

Handle a suspect pen as little as possible and do not discard any of these items, even the packaging. This same set becomes the evidence a regulator needs if something later turns out to be wrong.

Work through these seven checks in order. Each one is a warning sign on its own, and several failing together is a strong signal that a pen is not what it claims to be.

1. Confirm the supply channel: Check that the pen was dispensed by a licensed pharmacy, whether a retail chemist, hospital pharmacy or established online platform, against a valid prescription. A pen bought through Instagram, WhatsApp, a classified ad or a cross-border listing sits outside the regulated chain regardless of how convincing the box looks. Counterfeiters copy artwork. They cannot easily fake a licensed pharmacy invoice.
2. Match the invoice to the box: The pharmacy name and address should be real and licensed, and the batch number and expiry date on the bill should match the ones printed on the pack. A price that looks far below the going rate for a high-value biologic is itself a red flag that enforcement officials and the manufacturer have both highlighted.
3. Read the manufacturer and importer details: On a genuine Indian pack, the manufacturer is Eli Lilly and Company with a United States address, and the Indian importer and marketer is Eli Lilly and Company (India) Pvt Ltd, based in Gurugram, Haryana. The country of origin is the United States. A "made in India" origin line contradicts the approval record and should raise suspicion, not reassurance.
4. Check every batch, expiry and licence number: Indian labelling rules require a genuine pack to carry the brand name, strength, batch number, date of manufacture, date of expiry and a manufacturing or import licence number. A missing batch number, a smeared expiry, or a blank licence line is a strong indicator of tampering or counterfeiting.
5. Verify the cold chain and storage statement: Both the carton and the pen should state storage at 2 to 8 degrees Celsius and instruct that the product must not be frozen, and the pen should have reached you cold. In the Gurugram case, Haryana's drug regulator specifically noted that the seized counterfeit pens had not been kept at the required temperature range.
6. Inspect print quality: Officers who identified the Gurugram fakes did so through differences in colour shades, a blurred pen illustration, wrong font weights, and punctuation errors in the address and toll-free number. Look for misspellings, unfamiliar logos, or anything that looks inconsistent compared with known-genuine packaging.
7. Scan the 2D barcode if the pack carries one. Lilly's global guidance directs patients to scan the 2D barcode on the medicine package with a smartphone, which checks whether the serial number is consistent with medicines manufactured by Lilly. A scan returning a consistent result is a strong positive sign. What an absent barcode means is more nuanced, explained in the table below.

If any check fails, do not inject the pen. Keep it, its carton and your paperwork intact and move to the reporting steps below.

1. Missing 2D Barcode proves the pen is fake

What to know: A present, scannable barcode that matches Lilly's records is a strong positive sign.

The limitation: Mounjaro is not on India's notified Schedule H2 list as of 2026, so Indian law does not require this barcode on the pack. Therefore, a missing barcode is a warning sign, not proof that the pen is fake.

2. Scan the government code to confirm authenticity

What to know: Schedule H2 brands must carry barcodes encoding product, batch and manufacturer data

The limitation: There is currently no national government app that verifies Mounjaro authenticity. Lilly's portal is a manufacturer verification tool, not a government verification service.

3. A capital S in Storage identifies a genuine pen

What to know: Typography can be useful when comparing a suspected pack with known-genuine packaging.

The limitation: No manufacturer or regulator document identifies the capitalisation of “Storage” as an authenticity marker. It should therefore not be used as a standalone authenticity check.

In April 2026, Haryana's Food and Drugs Administration and Gurugram police intercepted a vehicle and seized spurious Mounjaro KwikPen injections spanning all six strengths. Reuters, citing Indian drug-control officers, reported that regulators confiscated over 260 suspected counterfeit pens. The suspect had manufactured the product at his residence, held no licence, and had kept the stock outside the required 2 to 8 degree range. Eli Lilly (India) confirmed the seized items were counterfeit and did not originate from its authorised supply chain.

One point matters for anyone reading alarm stories online: every confirmed Indian seizure concerns Mounjaro (tirzepatide). There is no confirmed Indian seizure of counterfeit Ozempic (semaglutide) in the official record as of mid-2026. International alerts on counterfeit semaglutide are separate events from other countries and should not be read as an Indian Ozempic problem.

If the checks leave you doubting a pen, treat it as suspect and act on that.

• Do not inject from it: Fake medicines can contain the wrong dose, contaminants, or a different molecule altogether, which carries real risk.
• Preserve everything: Keep the pen, carton, any needles and all paperwork. Do not return the product to the seller, which can destroy the evidence a regulator needs.
• Tell your prescribing doctor: Inform the clinician who prescribed the treatment, especially if you have already injected, so they can advise on any monitoring.
• Report it to the regulator: CDSCO directs consumers to its complaint email route and a toll-free line. Your State Drug Controller or State FDA runs a parallel complaint channel. Send clear photos of all faces of the carton and pen, the batch and expiry, and a note of any mismatch you spotted.
• Notify the manufacturer: Contact Lilly India through its official customer-service channel so it can validate the serial or batch and support any investigation.

The safest route is a documented clinical pathway.

When GLP-1 medication is prescribed and dispensed through a licensed channel under a registered clinician, most of the routes a counterfeit travels are closed before a pen reaches you. Voy India is built around exactly that model: clinician-led care in which medication, if a clinician decides it is appropriate, moves through a documented, supervised pathway. If you are uncertain about a pen you already hold, a consultation with a Voy registered clinician is the right next step.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.